<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422513</url>
  </required_header>
  <id_info>
    <org_study_id>ML20336</org_study_id>
    <nct_id>NCT00422513</nct_id>
  </id_info>
  <brief_title>A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.</brief_title>
  <official_title>A Randomized, Open-label Study Comparing the Pharmacoeconomic (Time and Motion) Benefit of Mircera and Epoetin Alfa in Patients With Chronic Kidney Disease (Stage V) on Dialysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 2 arm study will compare 'time and motion' (provider time spent on anemia management)
      and effect on hemoglobin (Hb) levels, of methoxy polyethylene glycol-epoetin beta (Mircera)
      and epoetin alfa, in anemic patients with chronic kidney disease (CKD) on hemodialysis.
      Patients stable on intravenous (iv) epoetin alfa will be randomized either to receive
      standard of care therapy (epoetin alfa (iv) 3 times weekly), or to receive Mircera 120-360
      micrograms (iv), monthly. After a titration period, average time spent on anemia treatment
      over a 3 month period will be evaluated. The anticipated time on study treatment is 3-12
      months, and the target sample size is 100-500 individuals.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Strategic decision unrelated to safety or efficacy
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Spent on Anemia Treatment Over Evaluation Period</measure>
    <time_frame>Months 5-7</time_frame>
    <description>Efficacy and pharmacoeconomics analyses were not performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hemoglobin (Hb) Concentration From Baseline to the Average Over the Evaluation Period</measure>
    <time_frame>Baseline, Months 5-7</time_frame>
    <description>Efficacy and pharmacoeconomics analyses were not performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Assessed for AEs</measure>
    <time_frame>Month 1 to 15 day follow up post month 7</time_frame>
    <description>The adverse events are captured in the adverse event and serious adverse event section of this database.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Marked Laboratory Abnormalities Occurring in â‰¥5% of the Participants</measure>
    <time_frame>Baseline, Month 1 to Month 7</time_frame>
    <description>A marked laboratory abnormality was defined as a test result that was outside of the marked abnormality range and that also represented a clinically relevant change from baseline of at least a designated amount.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>methoxy polyethylene glycol-epoetin beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120-360 micrograms (iv) monthly, starting dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin Alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As prescribed, (iv), 3 times weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methoxy polyethylene glycol-epoetin beta</intervention_name>
    <description>120-360 micrograms intravenous (iv) monthly, starting dose</description>
    <arm_group_label>methoxy polyethylene glycol-epoetin beta</arm_group_label>
    <other_name>Mircera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa</intervention_name>
    <description>As prescribed, iv, 3 times weekly</description>
    <arm_group_label>Epoetin Alfa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients, &gt;=18 years of age;

          -  CKD (stage V) on outpatient hemodialysis therapy for &gt;= 3 months;

          -  CKD-related anemia treated with epoetin alfa iv 3x/week for &gt;= 3 months;

          -  average hemoglobin (Hb) 10-12 g/dL over last 3 months.

        Exclusion Criteria:

          -  failed renal transplant within 12 months prior to screening;

          -  poorly controlled hypertension;

          -  previous treatment with Mircera.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rainbow City</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hot Springs</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hudson</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sparks</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn Center</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lewistown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Homestead</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2007</study_first_submitted>
  <study_first_submitted_qc>January 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <results_first_submitted>March 29, 2011</results_first_submitted>
  <results_first_submitted_qc>November 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 14, 2011</results_first_posted>
  <last_update_submitted>November 9, 2011</last_update_submitted>
  <last_update_submitted_qc>November 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Methoxy Polyethylene Glycol-epoetin Beta</title>
          <description>120-360 micrograms intravenous (iv) monthly, starting dose</description>
        </group>
        <group group_id="P2">
          <title>Epoetin Alfa</title>
          <description>As prescribed, (iv), 3 times weekly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>early termination of the study</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methoxy Polyethylene Glycol-epoetin Beta</title>
          <description>120-360 micrograms (iv) monthly, starting dose</description>
        </group>
        <group group_id="B2">
          <title>Epoetin Alfa</title>
          <description>As prescribed, (iv), 3 times weekly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="123"/>
            <count group_id="B2" value="129"/>
            <count group_id="B3" value="252"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Eight patients were excluded from the safety population: 7 patients in the Methoxy Polyethylene Glycol-epoetin Beta group and 1 patient in the epoetin alfa group. Six patients in the Methoxy Polyethylene Glycol-epoetin Beta group did not receive study medication. Seven patients in the Methoxy Polyethylene Glycol-epoetin Beta group and 1 patient in the epoetin alfa group did not have a postbaseline safety assessment.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="13.90"/>
                    <measurement group_id="B2" value="60.0" spread="14.06"/>
                    <measurement group_id="B3" value="59.7" spread="13.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time Spent on Anemia Treatment Over Evaluation Period</title>
        <description>Efficacy and pharmacoeconomics analyses were not performed.</description>
        <time_frame>Months 5-7</time_frame>
        <population>The safety population was the anticipated population analyzed. Efficacy and pharmacoeconomics analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-epoetin Beta</title>
            <description>120-360 micrograms (iv) monthly, starting dose</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>As prescribed, (iv), 3 times weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent on Anemia Treatment Over Evaluation Period</title>
          <description>Efficacy and pharmacoeconomics analyses were not performed.</description>
          <population>The safety population was the anticipated population analyzed. Efficacy and pharmacoeconomics analyses were not performed.</population>
          <units>months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin (Hb) Concentration From Baseline to the Average Over the Evaluation Period</title>
        <description>Efficacy and pharmacoeconomics analyses were not performed.</description>
        <time_frame>Baseline, Months 5-7</time_frame>
        <population>The safety population was the anticipated population analyzed. Efficacy and pharmacoeconomics analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-epoetin Beta</title>
            <description>120-360 micrograms (iv) monthly, starting dose</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>As prescribed, (iv), 3 times weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin (Hb) Concentration From Baseline to the Average Over the Evaluation Period</title>
          <description>Efficacy and pharmacoeconomics analyses were not performed.</description>
          <population>The safety population was the anticipated population analyzed. Efficacy and pharmacoeconomics analyses were not performed.</population>
          <units>g/dL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Assessed for AEs</title>
        <description>The adverse events are captured in the adverse event and serious adverse event section of this database.</description>
        <time_frame>Month 1 to 15 day follow up post month 7</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-epoetin Beta</title>
            <description>120-360 micrograms (iv) monthly, starting dose</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>As prescribed, (iv), 3 times weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Assessed for AEs</title>
          <description>The adverse events are captured in the adverse event and serious adverse event section of this database.</description>
          <population>Safety Population</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Marked Laboratory Abnormalities Occurring in â‰¥5% of the Participants</title>
        <description>A marked laboratory abnormality was defined as a test result that was outside of the marked abnormality range and that also represented a clinically relevant change from baseline of at least a designated amount.</description>
        <time_frame>Baseline, Month 1 to Month 7</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-epoetin Beta</title>
            <description>120-360 micrograms (iv) monthly, starting dose</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>As prescribed, (iv), 3 times weekly</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Marked Laboratory Abnormalities Occurring in â‰¥5% of the Participants</title>
          <description>A marked laboratory abnormality was defined as a test result that was outside of the marked abnormality range and that also represented a clinically relevant change from baseline of at least a designated amount.</description>
          <population>Safety Population</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit - low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin - low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets - low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Phosphokinase - high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium - high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fasting Glusose - high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate - high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate - low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Month 1 to 15 day follow up post month 7</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Methoxy Polyethylene Glycol-epoetin Beta</title>
          <description>120-360 micrograms (iv) monthly, starting dose</description>
        </group>
        <group group_id="E2">
          <title>Epoetin Alfa</title>
          <description>As prescribed, (iv), 3 times weekly</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>appendiccal mucocoele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>colonic pseudo-obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>diabetic gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>arteriovenous graft site infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>mental status change</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>vascular calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>vascular pseudoaneurysm ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>face oedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>&quot;The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

